AstraZeneca
AstraZeneca admits cancer data for acquired drug was fabricated
October 16, 2017Research and Development, Sales and Marketing Acerta, AstraZeneca, acalabrutinib
AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers …
AstraZeneca’s Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC
October 9, 2017Sales and Marketing AstraZeneca, Cancer, NSCLC, immunotherapy, lung cancer
AstraZeneca has announced that its targeted therapy, Tagrisso (osimertinib), has been awarded Breakthrough Therapy Designation by the FDA for the …
AstraZeneca Chairman wants three-year Brexit transition period
October 3, 2017Manufacturing and Production, Medical Communications AstraZeneca, biotech, brexit, drugs, pharma, pharmaceutical
The Chairman of AstraZeneca, Leif Johansson, revealed in no uncertain terms that his company would like there to be a …
New CMO hops onto Bicycle Therapeutics
September 26, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Bicycle Therapeutics, GSK, Pfizer, biotech, drugs, pharma, pharmaceutical
Bicycle Therapeutics has moved to appoint industry veteran, Maria Koehler, to the position of Chief Medical Officer at the company. …
AstraZeneca’s Forxiga displays potential in type 1 diabetes
September 14, 2017Research and Development AstraZeneca, Forxiga, biotech, drugs, farxiga, pharma, pharmaceutical
Forxiga is AstraZeneca’s treatment for those living with type 2 diabetes but the results from a new trial have found …
AstraZeneca’s Tagrisso beats standard of care in halting NSCLC
September 11, 2017Research and Development, Sales and Marketing AstraZeneca, ESMO, NSCLC, Tagrisso, non-small cell cell cancer, pharma, pharmaceutical
AstraZeneca has revealed new data at the European Society of Medical Oncology (ESMO) on the efficacy of Tagrisso (osimertinib) in …
Amgen and AstraZeneca’s experimental drug cuts asthma exacerbations by up to 71%
September 7, 2017Research and Development Amgen, AstraZeneca, MedImmune, asthma, pharma, pharmaceutical, tezepelumab
An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca’s global biologics and research division, MedImmune, has met its primary …
AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals
September 7, 2017Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial
AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …
NICE rejects AstraZeneca’s breast cancer drug Faslodex
September 1, 2017Medical Communications, Sales and Marketing AstraZeneca, Cancer, Faslodex, breast cancer, life sciences, pharma, pharmaceutical
NICE has announced its decision to not recommend AstraZeneca’s breast cancer drug Faslodex (fulvestrant) in women who have oestrogen-receptor-positive, locally …
AstraZeneca unloads another drug for $400m
August 29, 2017Research and Development, Sales and Marketing AstraZeneca, Takeda, biotech, drugs, pharma, pharmaceutical
AstraZeneca has had to do a serious re-think of its portfolio post-Mystic failure and it has made another move to …
AstraZeneca invests “tens of millions” into Cheshire, UK manufacturing site
August 29, 2017Manufacturing and Production, Research and Development AZ, AstraZeneca, Cheshire, Chesire, UK, life sciences, pharma, pharmaceuticals
AstraZeneca has announced plans to invest a multi-million sum into its £150 million facility in Macclesfield, Chesire, UK – a …
Extended use of AstraZeneca’s Brilinta reduces cardiovascular death risk
August 24, 2017Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, life sciences, pharma, pharmaceutical
New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk …
AstraZeneca strikes mRNA-based partnership in respiratory disease
August 22, 2017Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Ethris, MedImmune, mrna, pharma, pharmaceuticals
AstraZeneca and MedImmune, the company’s biologics research arm, have forged a five year research partnership with mRNA-based pulmonary disease specialist …
AZ and MSD secure three bits of good news on key drug
August 18, 2017Medical Communications, Sales and Marketing AstraZeneca, MSD, biotech, drugs, pharma, pharmaceutical
It was a case of three-in-one bits of good news for AstraZeneca and MSD, after the FDA boosted the newly …
AstraZeneca’s Priority Review good news provides reprieve
August 2, 2017Sales and Marketing AstraZeneca, FDA, biotech, drugs, pharma, pharmaceutical
If there was a company that needed a series of good news stories this week, it was AstraZeneca. The blow …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
